Sirolimus Eluting BioResorbable Vascular Scaffold System

  • 0%


  • 0%


  • 0%



Overview of BRS

Currently used metallic drug eluting stents stays permanently in blood vessels This may not only lead to increased risk of adverse events year on year, but may also pose a hindrance if future procedures need to be performed in the same artery. However, newer type of stents, called bioresorbable scaffolds (BRS) provides a temporary scaffold to the lesion to restore the blood flow, once the vessel blockage is treated and healing is completed, BRS dissolves fully, leaving the artery in its natural state with no foreign residue. This provides both physicians and patients the room to explore future treatment interventions, if required, in the same blood vessel..

Evolution of PCI

Invention of plain ‘old’ balloon angioplasty (POBA) indicated the first revolution in the treatment of CAD through the skin. Despite successful dilation and coronary flow restoration to the diseased coronary artery, interest in this innovative technology was lost by issues related to acute vessel closure caused by vascular elastic recoil occurred in 5–10% of patients immediately after the procedure, and development of neointimal proliferation with restenosis occurred in ~30% of patients within the first six months.

Bare metal stents (BMS) began the second revolution in the treatment of CAD as a resource to overcome the restrictions of POBA. Though, BMS resolved the issue of acute vessel occlusion, it was accompanied by major problem of in-stent restenosis (ISR). Though studies have proven that BMS implantations were superior to balloon angioplasty alone but in-stent restenosis due to neointimal proliferation was still high at the rate of 20–30%

Drug eluting stents (DES) – the third revolution in PCI – were considered as tools to solve the treatment-related issues of BMS and reduce the restenosis risk. Landmark evidence of the first generation sirolimus-eluting stents established significant reduction in vessel wall thickening due to the healing response and risk of restenosis versus the BMS. Later, the indications for DES rapidly arose, with the use of DES accepted in more complex CAD and higher risk patient groups. Despite the favorable results associated with the first generation DES, safety issues also arose, especially the risk of late stent thrombosis. The crucial concerns with the first generation DES were related 1) to the absence of biocompatibility of the drug eluting polymer causing a long-standing inflammation beyond the drug eluting period of the device, 2) to a risk of a continued scar tissue formation and risk of a ‘late-catch up’ phenomenon and late ISR, and 3) to a delayed/incomplete healing, and risk of late/very late stent thrombosis. Additionally, other issues were identified including abnormal vessel movement, explained by the endothelial layer’s abnormal function.

Even newer generation DES, did not fully resolve these concerns, especially the longer term risk of DES failure due to long-term inflammation in the vessel wall caused by the stent itself, resulting in clot formation (neo-atherosclerosis).

Bioresorbable scaffolds (BRS) heralded the fourth revolution in interventional cardiology. They were ultimately designed to overcome the perceived limitations of DES by providing a temporary support to the vessel wall, whilst simultaneously allowing for the release of an anti-proliferative drug to limit the excessive response, in order to potentially allow the vessel to heal and restore its physiological function.

The promise of BRS: Unique Chemistry

The BRS is mostly composed of repeating units of bioresorbable polymers. After implantation of BRS, bonds between repeating units in the polymer structure of these scaffolds begin to get hydrolyzed producing lactic acid, which is metabolized via Krebs cycle and get converted to carbon dioxide and water.

Chemically, scaffold absorption takes place in three phases; initially water starts breaking down chemical bonds, resulting in decrease of stent’s molecular weight. In the second stage there is decline in radial strength. At third stage, residual short polymer chains diffuse out of the device to get reabsorbed into blood.

Degradation of scaffold governs mechanical performance, which is divided into three phases: during initial “Rebuilt phase”, it acts like a typical drug eluting stent (comparable deliverability, minimal acute recoil and high radial strength. In this phase the objective is to treat the lesion & restore blood flow.

At the Revive phase, there is breaking of connecting points, causing a decline in radial strength. this phase takes three to six months post implantation. During the last “Renew phase” the BRS becomes discontinuous and ceases to act as a scaffold. It gets completely resorbed by natural process (except the small platinum markers for future fluoroscopic identification of treated vessel) gets eliminated as as Carbon di oxide and water. Renew Phases may take 24 to 36 months.


MERES100 Angioplasty- Treatment for Coronary Artery Disease

Advantages of Bioresorbable Scaffolds (BRS)

Traditional metal stents have been associated with several drawbacks for a long time. A metallic stent needs to be placed permanently in the blood vessel for prevention of vessel recoil and re-narrowing, post dilating a clogged artery with a balloon. However, the permanent presence of a metal stent becomes a nidus for forming a clot of blood within the stent which could be fatal for the patient. The chief advantage of using a dissolving stent/BRS is freedom from the permanent presence of a metallic stent in the artery.

As a dissolving stent/BRS disappears after its intended use, it removes the potential reason of inflammation that may be responsible for late stent thrombosis or restenosis. As the stent gets dissolved, it restores the usual state of the artery with its original vessel constriction and dilation. The dissolving stent also preserves all options of future re-interventions. Majority of the dissolving stents are composed from polylactic acid which is a dissolvable polymer, successfully tested in medical devices such as sutures.

BRS allow for successful acute revascularization of coronary artery stenosis and in evidence, they have been shown to be associated with low rates of repeat angioplasty requirements and major adverse cardiac events (MACE) during the early follow-up period. The main advantage of the BRS is that following complete bioresorption, no foreign body remains in the vessel wall at long term follow-up, which may ease the increased long term risk of stent thrombosis seen with the first generation DES.

Furthermore, the treated vessel may show a possible restoration in its vasomotor function when the structural integrity of the BRS has been appropriately lost.

Another useful property of BRS is that it allows for a non-invasive imaging without any significant imaging objects. Additionally, BRS potentially allows the surgeons to attach surgical connection to the segments under the scaffold (anastomoses), once the bioresorption process has been completed.

Safety and Effectiveness of Bioresorbable Scaffolds (BRS) in Clinical Evidence

The impression of the BRS is rational and smart. The outcomes of BRS at short- and medium-term (up to 3 years) are encouraging. Safety and efficacy is proven up to three years 0% scaffold thrombosis both in Indian and International patients. However, its long-term safety rests unidentified. Hence, more randomised long-term clinical evidence is needed to define whether the theoretical advantage of the BRS can be converted into routine practice. Moreover, the superiority of the BRS over the second-generation DES is not yet established with confidence. Hence, currently use of the BRS can be considered in a wisely selected group of patients matching those in published clinical trials, with stringent observance to an ideal implantation technique.

Product Specifications

Stent design  
Stent Material and Thickness Bioresorbable PLLA (Poly L-lactide) , 100 microns
Stent Architecture Hybrid Design: Closed cells on ends and open cells in middle
Drug Sirolimus
Drug Dose 1.25μg/mm2
Drug coating Proprietary top coat
Delivery system Rapid Exchange


Size Chart

DIAMETER / LENGTH 13 MM 16 MM 19 MM 24 MM 29 MM 32 MM 37 MM 40 MM
2.50 mm  MRS25013 MRS25016 MRS25019 MRS25024 MRS25029 MRS25032 MRS25037 MRS25040
2.75 mm MRS27513 MRS27516 MRS27519 MRS27524 MRS27529 MRS27532 MRS27537 MRS27540
3.00 mm MRS30013 MRS30016 MRS30019 MRS30024 MRS30029 MRS30032 MRS30037 MRS30040
3.25 mm MRS32513 MRS32516 MRS32519 MRS32524 MRS32529 MRS32532 MRS32537 MRS32540
3.50 mm MRS35013 MRS35016 MRS35019 MRS35024 MRS35029 MRS35032 MRS35037 MRS35040
4.00 mm MRS40013 MRS40016 MRS40019 MRS40024 MRS40029 MRS40032 MRS40037 MRS40040
4.50 mm MRS45013 MRS45016 MRS45019 MRS45024 MRS45029 MRS45032 MRS45037 MRS45040

Contact your country local Meril sales representative for availibility of sizes highlighted in blue

Clinical Data

Study Name Type of Study Total Patients Status LINKS
Sponsor Initiated Studies
MeRes-1 Study First-in-man 108 Ongoing Know more
MeRes-1 Extend Study Global Study 64 Ongoing Know more


Product IFU

Note: IFU will be displayed after MDR Certification